^
Association details:
Biomarker:No biomarker
Cancer:Triple Negative Breast Cancer
Drug:samuraciclib (CT7001) (CDK7 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

CARRICK THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATIONS FOR TWO SAMURACICLIB COMBINATIONS FOR THE TREATMENT OF HR+, HER2- ADVANCED BREAST CANCER AND LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER

Published date:
08/16/2021
Excerpt:
Carrick Therapeutics...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC).
Secondary therapy:
Chemotherapy